We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

438 hedge funds and large institutions have $15.8B invested in BioMarin Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 150 increasing their positions, 145 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 44

34% more call options, than puts

Call options by funds: $208M | Put options by funds: $155M

33% more funds holding in top 10

Funds holding in top 10: 9 → 12 (+3)

7% more funds holding

Funds holding: 411 → 438 (+27)

1.4% more ownership

Funds ownership: 99.72% → 101.12% (+1.4%)

3% more repeat investments, than reductions

Existing positions increased: 150 | Existing positions reduced: 145

3% less capital invested

Capital invested by funds: $16.3B → $15.8B (-$449M)

Holders
438
Holders Change
+27
Holders Change %
+6.57%
% of All Funds
9.93%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.27%
New
78
Increased
150
Reduced
145
Closed
44
Calls
$208M
Puts
$155M
Net Calls
+$52.8M
Net Calls Change
+$34.5M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$146M
2
BlackRock
BlackRock
New York
+$81.5M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$60M
4
Citadel Advisors
Citadel Advisors
Florida
+$58.4M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$56.5M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$178M
2
SIG
Senator Investment Group
New York
-$65.1M
3
O
OrbiMed
New York
-$55.9M
4
Jennison Associates
Jennison Associates
New York
-$43.9M
5
Bank of America
Bank of America
North Carolina
-$43.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
DZ Bank
176
DZ Bank
Germany
$2.67M +$2.61M +30,000 New
SF
177
Synovus Financial
Georgia
$2.54M +$428K +4,918 +21%
ANI
178
American National Insurance
Texas
$2.5M – – –
CIBC Private Wealth Group
179
CIBC Private Wealth Group
Georgia
$2.48M +$558K +6,413 +30%
TMAM
180
Tokio Marine Asset Management
Japan
$2.48M -$35.1K -404 -1%
DCM
181
Dynamic Capital Management
Jersey
$2.34M -$782K -8,990 -25%
OAM
182
Oppenheimer Asset Management
New York
$2.32M – – –
CM
183
Caption Management
Oklahoma
$2.23M +$2.17M +25,000 New
XK
184
Xact Kapitalforvaltning
Sweden
$2.07M +$192K +2,212 +11%
Retirement Systems of Alabama
185
Retirement Systems of Alabama
Alabama
$2.04M – – –
SAM
186
Shell Asset Management
Netherlands
$2.03M +$265K +3,042 +15%
MSV
187
MN Services Vermogensbeheer
Netherlands
$2.02M -$130K -1,500 -5%
EU
188
Emory University
Georgia
$1.97M +$205K +2,354 +12%
CWM
189
CMH Wealth Management
New Hampshire
$1.95M -$3.91K -45 -0.2%
AB
190
Amalgamated Bank
New York
$1.81M +$178K +2,052 +11%
B
191
BP
United Kingdom
$1.78M – – –
VSI
192
Verde Servicos Internacionais
Brazil
$1.75M +$1.7M +19,570 New
HT
193
HAP Trading
New York
$1.74M +$1.7M +19,511 New
SOADOR
194
State of Alaska Department of Revenue
Alaska
$1.67M +$1.14M +13,080 +233%
CBB
195
Citizens Business Bank
California
$1.66M -$73.3K -843 -4%
DnB Asset Management
196
DnB Asset Management
Norway
$1.63M – – –
FIM
197
Freedom Investment Management
Connecticut
$1.62M +$44.7K +514 +3%
Natixis Advisors
198
Natixis Advisors
Massachusetts
$1.59M +$1.04K +12 +0.1%
GT
199
Glenmede Trust
Pennsylvania
$1.56M +$54.1K +622 +4%
AIG
200
American International Group
New York
$1.53M +$361K +4,154 +32%
6 7
8
9 10

BMRN Hedge Fund Activity: Q4 2017 in Review

438 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2017, worth a combined $15.8B — down 2.8% from $16.3B a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new BMRN positions and 44 closed out — a net gain of 34 holders — while 150 added to existing stakes and 145 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $146M. The largest seller was Fidelity Investments, cutting an estimated $178M.

  • 438 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2017, up from 411 in Q3 2017.
  • Funds reported $15.8B of BioMarin Pharmaceuticals stock for Q4 2017, down 2.8% quarter-over-quarter.
  • 78 funds opened new BioMarin Pharmaceuticals positions in Q4 2017 and 44 closed out, a net change of +34 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2017 was Baker Bros. Advisors, an estimated $146M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $178M sold.

Based on aggregated 13F filings for Q4 2017.